Peptide Therapeutics Market Trends, Revenue, Analysis Report 2024-2032

IMARC Group’s report titled “Peptide Therapeutics Market Report by Type (Innovative, Generic), Type of Manufacturer (Outsourced, In-House), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), Routes of Administration (Parenteral, Oral, and Others), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Others), and Region 2024-2032”. The global peptide therapeutics market size reached US$ 42.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 86.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.

Grab a sample PDF of this report: https://www.imarcgroup.com/peptide-therapeutics-market/requestsample

Factors Affecting the Growth of the Peptide Therapeutics Industry:

• Increasing Prevalence of Chronic Diseases:

Conditions, such as cancer, diabetes, cardiovascular diseases, and metabolic disorders, are becoming more common worldwide due to aging populations, lifestyle changes, and genetic factors. Peptide therapeutics offer high specificity, low toxicity, and the ability to mimic natural biological processes, delivering promising treatment options for these chronic diseases. In addition, peptide-based drugs are used in diabetes management to regulate blood sugar levels and in cancer therapy to target specific tumor cells without harming healthy tissues. The growing burden of chronic diseases necessitates the development of effective and targeted treatments, driving the demand for peptide therapeutics.

• Advances in Biotechnology and Drug Delivery Systems:

Innovations in peptide synthesis, recombinant deoxyribonucleic acid (DNA) technology, and peptide engineering are improving the stability, efficacy, and bioavailability of peptide-based drugs. Furthermore, novel drug delivery systems, including nanoparticles, liposomes, and injectable depots, are enhancing the controlled release and targeted delivery of peptide therapeutics. These technological advancements overcome the traditional challenges associated with peptide drugs, such as rapid degradation and poor membrane permeability. The growing focus on developing more effective and convenient peptide therapies for expanding their application in various therapeutic areas is positively influencing the market.

• Growing Investment and Collaboration in Peptide Research:

Pharmaceutical companies, biotech firms, and research institutions are investing in peptide-based drug discovery and development due to the high therapeutic potential of peptides. Collaborations between academia and industry, along with government funding and grants, are accelerating the research and development (R&D) of novel peptide therapeutics. These partnerships facilitate knowledge sharing, access to advanced technologies, and the translation of scientific discoveries into clinical applications. The robust pipeline of peptide drugs under development and the success of approved peptide therapeutics in the market are attracting investment.

Leading Companies Operating in the Global Peptide Therapeutics Industry:

• Amgen Inc.

• Apitope International NV

• Arch Biopartners Inc.

• AstraZeneca plc

• Circle Pharma Inc.

• Corden Pharma GmbH

• F. Hoffmann-La Roche AG

• Ipsen Group

• Lonza Group AG

• Novo Nordisk A/S

• Pfizer Inc.

• Teva Pharmaceuticals Industries Ltd.

• Zealand Pharma A/S.

Peptide Therapeutics Market Report Segmentation:

By Type:

• Innovative

• Generic

Innovative exhibits a clear dominance in the market driven by the advanced therapeutic potential and higher investment in research operations.

By Type of Manufacturer:

• Outsourced

• In-house

In-house represents the largest segment accredited to the preference of companies to maintain control over production quality and intellectual property.

By Synthesis Technology:

• Solid Phase Peptide Synthesis

• Liquid Phase Peptide Synthesis

• Hybrid Technology

Liquid phase peptide synthesis holds the biggest market share attributed to its flexibility and efficiency in producing a wide range of peptide sequences.

By Routes of Administration:

• Parenteral

• Oral

• Others

Parenteral accounts for the majority of the market share, as it offers direct and efficient delivery of peptides that are otherwise poorly absorbed orally.

By Application:

• Gastrointestinal Disorders

• Neurological Disorders

• Metabolic Disorders

• Cancer

• Others

Cancer represents the largest segment due to the high demand for targeted therapies and the rising investment in oncology research.

Regional Insights:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

North America dominates the market owing to its advanced healthcare infrastructure, high R&D investments, and the presence of major pharmaceutical companies.

Global Peptide Therapeutics Market Trends:

Traditional peptide drugs often focus on a single target, which encourages researchers to explore peptides that can interact with multiple biological targets simultaneously, enhancing therapeutic efficacy and reducing the potential for drug resistance. Additionally, the integration of peptides with other therapeutic modalities, including monoclonal antibodies and small molecules, is creating hybrid therapies that combine the strengths of each approach for more comprehensive treatment solutions.

Furthermore, the growing use of advanced computational tools and artificial intelligence (AI) in peptide drug design is offering a favorable market outlook. AI and machine learning (ML) algorithms are employed to predict peptide interactions, optimize drug formulations, and accelerate the discovery process.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163